{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T02:03:33Z","timestamp":1767146613282,"version":"build-2238731810"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T00:00:00Z","timestamp":1630108800000},"content-version":"vor","delay-in-days":239,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research Reports"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/j.lrr.2021.100266","type":"journal-article","created":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T11:37:30Z","timestamp":1630323450000},"page":"100266","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Sustained MRD negative remission in del17p and TP53 mutated B cell prolymphocytic leukemia with ibrutinib and venetoclax"],"prefix":"10.1016","volume":"16","author":[{"given":"Maria Tariq","family":"Siddiqui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allyson","family":"Price","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Ferrajoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gautam","family":"Borthakur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lrr.2021.100266_bib0001","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.beha.2019.06.001","article-title":"B and T cell prolymphocytic leukaemia","volume":"32","author":"Cross","year":"2019","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.lrr.2021.100266_bib0002","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/ajh.20843","article-title":"Complete response to alemtuzumab in a patient with B prolymphocytic leukemia [7]","volume":"82","author":"Chaar","year":"2007","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.lrr.2021.100266_bib0003","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/bjh.15151","article-title":"Idelalisib-rituximab induces durable remissions in TP53 disrupted B-PLL but results in significant toxicity: updated results of the UK-wide compassionate use programme","volume":"184","author":"Eyre","year":"2019","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.lrr.2021.100266_bib0004","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/bjh.15802","article-title":"Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis","volume":"185","author":"Eyre","year":"2019","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.lrr.2021.100266_bib0005","unstructured":"J. Swerdlow, S.H.; Campo, E.; Harris, N.L.; Jaffe, E.S.; Pileri, S.A.; Stein, H.; Thiele, J.; Vardiman, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed., 2008."},{"key":"10.1016\/j.lrr.2021.100266_bib0006","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.4065\/80.12.1660","article-title":"Chronic lymphoid leukemias other than chronic lymphocytic leukemia: diagnosis and treatment","volume":"80","author":"Ravandi","year":"2005","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.lrr.2021.100266_bib0007","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3109\/10428199909093739","article-title":"B-Cell prolymphocytic leukemia: a survey of 35 patients emphasizing heterogeneity, prognostic factors and evidence for a group with an indolent course","volume":"33","author":"Shvidel","year":"1999","journal-title":"Leuk. Lymphoma."},{"key":"10.1016\/j.lrr.2021.100266_bib0008","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1182\/blood-2012-01-380139","article-title":"How I treat prolymphocytic leukemia","volume":"120","author":"Dearden","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.lrr.2021.100266_bib0009","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/sj.leu.2404238","article-title":"IgVH genes mutation and usage, ZAP-70 and CD38 expression provide new insights on B-cell prolymphocytic leukemia (B-PLL)","volume":"20","author":"Del Giudice","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.lrr.2021.100266_bib0010","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.1182\/blood.V88.10.3953.bloodjournal88103953","article-title":"High frequency of somatic mutations in the VH genes expressed in prolymphocytic leukemia","volume":"88","author":"Davi","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.lrr.2021.100266_bib0011","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s00277-011-1393-y","article-title":"Chronic lymphocytic leukemia and prolymphocytic leukemia with MYC translocations: a subgroup with an aggressive disease course","volume":"91","author":"Put","year":"2012","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.lrr.2021.100266_bib0012","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1309\/AJCPUBHM8U7ZFLOB","article-title":"Aberrations of MYC are a common event in B-cell prolymphocytic leukemia","volume":"142","author":"Flatley","year":"2014","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.lrr.2021.100266_bib0013","first-page":"1821","article-title":"Genetic characterization of B-cell prolymphocytic leukemia: a prognostic model involving MYC and TP53","volume":"134","author":"Chapiro","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.lrr.2021.100266_bib0014","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/jnci\/85.8.658","article-title":"Pentostatin in prolymphocytic leukemia: phase II trial of the European organization for research and treatment of cancer leukemia cooperative study group","volume":"85","author":"D\u00f6hner","year":"1993","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.lrr.2021.100266_bib0015","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00277-008-0541-5","article-title":"A combination therapy with fludarabine, mitoxantrone and rituximab induces complete immunophenotypical remission in B-cell prolymphocytic leukaemia","volume":"88","author":"Tempescul","year":"2009","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.lrr.2021.100266_bib0016","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1600-0609.2011.01680.x","article-title":"Clinical efficacy of immunochemotherapy with fludarabine, epirubicin and rituximab in the treatment for chronic lymphocytic leukaemia and prolymphocytic leukaemia","volume":"87","author":"Chow","year":"2011","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.lrr.2021.100266_bib0017","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1080\/10428190290021597","article-title":"Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia","volume":"43","author":"McCune","year":"2002","journal-title":"Leuk. Lymphoma."},{"key":"10.1016\/j.lrr.2021.100266_bib0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/8563218","article-title":"Sequential kinase inhibition (idelalisib\/ibrutinib) induces clinical remission in b-cell prolymphocytic leukemia harboring a 17p deletion","volume":"2017","author":"Coelho","year":"2017","journal-title":"Case Rep. Hematol."},{"key":"10.1016\/j.lrr.2021.100266_bib0019","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/bjh.14224","article-title":"Ibrutinib is an effective treatment for B-cell prolymphocytic leukaemia","volume":"179","author":"Gordon","year":"2017","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.lrr.2021.100266_bib0020","article-title":"B-cell prolymphocytic leukemia: case report and challenges on a diagnostic and therapeutic forefront","volume":"11","author":"Bindra","year":"2019","journal-title":"Cureus."},{"key":"10.1016\/j.lrr.2021.100266_bib0021","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1007\/s10637-020-00902-9","article-title":"Effective upfront treatment with low-dose ibrutinib for a patient with B cell prolymphocytic leukemia","volume":"38","author":"Oka","year":"2020","journal-title":"Invest. New Drugs."},{"key":"10.1016\/j.lrr.2021.100266_bib0022","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","article-title":"Ibrutinib and Venetoclax for First-Line Treatment of CLL","volume":"380","author":"Jain","year":"2019","journal-title":"N. Engl. J. Med."}],"updated-by":[{"DOI":"10.1016\/j.lrr.2022.100309","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000}}],"container-title":["Leukemia Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048921000339?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048921000339?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,1,9]],"date-time":"2022-01-09T02:42:52Z","timestamp":1641696172000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213048921000339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":22,"alternative-id":["S2213048921000339"],"URL":"https:\/\/doi.org\/10.1016\/j.lrr.2021.100266","relation":{},"ISSN":["2213-0489"],"issn-type":[{"value":"2213-0489","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sustained MRD negative remission in del17p and TP53 mutated B cell prolymphocytic leukemia with ibrutinib and venetoclax","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lrr.2021.100266","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100266"}}